Previous studies from our lab have shown that HER2 peptide pulsed-DC1 (HER2-DC1) vaccine induced 30% complete response (pCR) in DCIS patients. However, little is known about the effect of HER2-DC1 vaccine on DCCs. Here, we investigated the efficacy of HER2-DC1 vaccine on DCCs in a ...
the expression of HER2 has been significantly reduced for most immunized patients suggesting HER2 DC vaccine treatment either promoting destruction of cancer cells or suppressing expression of HER2.117 Recently, HER2 peptide-pulsed DC1 vaccine has been further tested in HER2-positive DCIS breast cancer ...
Interestingly, Czerniecki et al. showed anti-HER2 CD4+Th1 immunity to be a relevant component of HER2+therapy, as loss of CD4+Th1 responses correlated with poor prognosis and treatment responses15. The administration of a class II HER2 peptide-pulsed Type I polarized DC1 vaccine was shown to ...
Three main peptides derived from the protein structure of HER2 have been used to develop BC vaccines. The E75 and GP2 peptides, which are HLA-A2/A3-restricted, and AE37, which is a promiscuous HLA class II binder [168,169,170]. These peptides are located on the extra-cellular domain ...
Th1 response metrics were anti-HER2 responsivity, repertoire (number of reactive peptides), and cumulative response across 6 peptides (spot-forming cells [SFC]/106 cells). Anti-HER2 Th1 responses of non-pCR patients (n = 4) receiving adjuvant HER2-pulsed type 1-polarized dendritic cell (DC1...
HER2 peptide pulsed type I dendritic cells (HER2-DC1) restored anti-HER2 CD4+ Th1 immune response and improved pathologic complete response (pCR) in HER2+ BC. Antibodies to SEMA4D have been shown to modulate the TME by increasing effector cell infiltration and reducing immunosuppression. In ...
HER2 peptide pulsed type I dendritic cells (HER2-DC1) restored anti-HER2 CD4+ Th1 immune response and improved pathologic complete response (pCR) in HER2+ BC.1 Antibodies to SEMA4D have been shown to modulate the TME by increasing effector cell infiltration and reducing immunosuppression.1 In ...
MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancerLiposomal vaccineHER2/neu peptidePADRE peptideBreast cancerCancer immunotherapyCancer vaccineLiposomal peptide-based vaccines can potentially suppress cancer cells ...
Enhanced immune response induced by P5 HER2/neu‐derived peptide‐pulsed dendritic cells as a preventive cancer vaccinedoi:10.1111/jcmm.13343Zahra GholizadehJalil Tavakkol-AfshariAmin Reza NikpoorSeyed Amir JalaliMahmoud Reza JaafariJ Cell Mol Med...
55 dendritic cell-based vaccine dendritic cells pulsed with HER-2/neu HLA class I and II peptides and activated in vitro with IFN-γ and bacterial lipopolysaccharide to become highly polarized DC1-type dendritic cells that secrete high levels of interleukin-12p70 available results of phase I ...